The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), who are frequently on long-term immunotherapies. Treatment with IVIg does not increase the risk of contracting COVID-19, and the IVIg administration may have a protective role. However, infusions can expose patients to an increased risk of contracting SARS-CoV-2 due to repeated access to Health Facilities. In this report we analyzed the short-term follow-up of CIDP patients who modified their chronic IVIg therapy during pandemic. About half of CIDP patients regularly treated with IVIg tried to stop treatment and about 10% shifted to SCIg. Forty-two percent of the patients who stopped the treatment reported a clinical deterioration after suspension and had to restart IVIg. This study demonstrated that in selected cases it is possible to successfully stop the chronic IVIg treatment, even in patients who have been treated for several years.

由新型冠状病毒（COVID-19）引起的严重急性呼吸系统综合症的爆发，对于经常进行长期免疫治疗的慢性炎性脱髓鞘性多发性神经根神经病（CIDP）患者引起了健康问题。IVIg的治疗不会增加感染COVID-19的风险，IVIg的给药可能具有保护作用。但是，由于反复进入医疗机构，输液会使患者患上SARS-CoV-2的风险增加。在本报告中，我们分析了在大流行期间修改其慢性IVIg治疗的CIDP患者的短期随访情况。定期接受IVIg治疗的CIDP患者中约有一半试图停止治疗，而约有10％的患者转用了SCIg。停止治疗的患者中有42％的患者在停药后报告临床恶化，必须重新启动IVIg。这项研究表明，在某些情况下，即使已经治疗了几年的患者，也可能成功停止慢性IVIg治疗。